Arcellx, Inc. (ACLX)
NEGATIVEFundamental
~0
Precio
$-
Capitalización Bursátil
-
Parte 1 · Cuánto vale la empresa
Resumen
No hay descripción disponible.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Datos financieros limitados disponibles (0% de las métricas). Las puntuaciones pueden no reflejar con precisión los fundamentos de esta empresa.
Balance y Liquidez
Ingresos
-
Beneficio Neto
-
Flujo de Caja Libre
-
Patrimonio Neto Total
-
Pasivo Total
-
Ratio de Liquidez
4.44
Cobertura de Intereses
-
Deuda/EBITDA
-
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Métricas de Valoración
Ratio P/E
-
ROE
-55.5%
Ratio P/B
-
P/FCF
-
Margen Bruto
-
ROIC
-
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
-
WACC
8.0%
ROIC − WACC
-
Criterios de Análisis Fundamental
Superado (0)
Fallido (0)
No disponible (1)
- Error fetching data
Piotroski F-Score
Preocupaciones financieras graves
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Gobernanza
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for ACLX, sourced from Markets Gazette.
- 3/2/2026POSITIVEArcellx President Sells $10M Worth of Shares After Acquisition Announcement
Arcellx Inc. shares have experienced a remarkable 75% surge in 2026, a significant jump directly linked to the company's impending acquisition, which will result in its delisting from the market. This development typically provides a premium for shareholders, a common outcome in M&A transactions. The President of Arcellx capitalized on this situation by selling $10 million worth of shares. While insider sales can sometimes be viewed negatively, in this context, it appears to be a logical consequence of the acquisition, which has already propelled the stock to elevated levels, making it soon untradable on public exchanges.
- 2/25/2026POSITIVEGilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy
Markets Gazette reports that Arcellx (ACLX) shares experienced a modest uplift following the announcement of its acquisition by Gilead Sciences. The biopharmaceutical giant has agreed to purchase Arcellx for a substantial $7.8 billion, translating to $115 per share in cash. This strategic move underscores Gilead's significant investment in the burgeoning field of cancer therapy, particularly in Arcellx's innovative pipeline. For investors, this deal represents a clear positive catalyst for Arcellx, offering a premium valuation and immediate liquidity, while positioning Gilead for potential long-term growth in oncology.
via Markets Gazette